drugset / Trial / NCT00283049

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

NCT00283049

Phase 4 Terminated 390 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.

Timeline

Start
2006-02
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic Subcutaneous
Background Insulin glulisine Protein / enzyme biologic